Read the full stored bill text
****
69th Legislature 2025 SB 353.1
- 1 - Authorized Print Version – SB 353
1 SENATE BILL NO. 353
2 INTRODUCED BY K. BOGNER
3
4 A BILL FOR AN ACT ENTITLED: “AN ACT REVISING THE RIGHT TO TRY ACT; LIMITING THE
5 TREATMENT OF MINORS WHO HAVE A TERMINAL ILLNESS WITH AN INVESTIGATIONAL DRUG,
6 BIOLOGICAL PRODUCT, OR DEVICE; AND AMENDING SECTION 50-12-104, MCA.”
7
8 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MONTANA:
9
10Section 1. Section 50-12-104, MCA, is amended to read:
11 "50-12-104. Patient requirements. (1) A patient is eligible for treatment with an investigational drug,
12 biological product, or device if the patient has:
13 (1)(a) considered all other treatment options currently approved by the United States food and drug
14 administration;
15 (2)(b) received a recommendation from the patient's treating health care provider for an
16 investigational drug, biological product, or device;
17 (3)(c) given written informed consent for the use of the investigational drug, biological product, or
18 device; and
19 (4)(d) documentation from the treating health care provider that the patient meets the requirements of
20 this section.
21 (2) A minor is not eligible for treatment with an investigational drug, biological product, or device
22 unless the minor has a terminal illness that is attested to by the minor's treating health care provider."
23 - END -